NGEN · NervGen Pharma Corp
United States · RS rating 13 · As of 2026-11-03
| Price | 1.32 USD |
|---|---|
| 1-day change | -2.2% |
| RS rating (overall / 1M / 3M / 12M) | 13 / 14 / 29 / 23 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 17 / 9 / 10 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -255.6% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +77.9% |
| Market cap (USD) | $318.1M |